Articles

An industry wide ecosystem report and survey was conducted with over 200 Subject Matter Experts, Key Opinion Leaders, Academic Cancer Care Centers, Community Cancer Providers, Revenue Cycle Management Companies, Pharmaceutical Manufacturers, National and Regional Insurance Companies, Personalized Medicine, Employers, Government Agencies, and Policy Influencers.

Panel discussion by key subject matter experts on the path ahead in terms headwinds and tailwinds for the advancement of value-based agreements. The panel will focus on the collaborative opportunities for participation by pharmaceutical manufacturers, healthcare innovators, diagnostic, and other telehealth and artificial intelligence technologies.

Typically, value-based agreements tend to be between pharmaceutical companies and insurance companies, and we will continue to see the evolution of these to include other key players such as employers, health systems, etc. But what about the patients?

Pharmaceutical and biotech innovators will face much different healthcare market dynamics on the path to commercialization ahead. Pharmaceutical innovators, providers and payer partners will have to be prepared to adapt and overcome the legacy challenges to participate in value-based agreements. Engaging with providers as partners vs. merely customers is also new.

Artificial Intelligence could significantly reduce inefficiency in healthcare, improve patient flow and experience, and enhance caregiver experience and patient safety through the care pathway. It can even get life-saving treatments to market faster.

This panel discussion is on the approach MassHealth took in creating value-based agreements. MassHealth had the legislative authority to directly negotiate with pharmaceutical manufacturers based on the proposed value of the drug. This presentation will review the path MassHealth took from planning, negotiating, and implementing supplemental value-based agreements.

This session will discuss access challenges for Medicaid patients.

This session will take a deeper dive of pediatrics and the future in cancer care.

President Joe Biden has authorized the relaunching the Cancer Moonshot, a program to reduce cancer deaths by 50% over the next 25 years and improve the experience of living with and surviving cancer. This session will summarize the goals and objectives of revitalized moonshot.

Former Assistant to the President, Director of the Domestic Policy Council, Joe Grogan, will be giving a simple explanation of the BBBA / IRA and the impact on the healthcare ecosystem.